Article

Comparative modeling of TNFRSF25 (DR3) predicts receptor destabilization by a mutation linked to rheumatoid arthritis.

Department of Pathology, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Biochemical and Biophysical Research Communications (Impact Factor: 2.28). 04/2005; 328(3):794-9. DOI: 10.1016/j.bbrc.2005.01.017
Source: PubMed

ABSTRACT We constructed a three-dimensional model of TNFRSF25 (death receptor-3; DR3), a tumor necrosis-receptor family member that is expressed on immune cells and on osteoblasts, to determine whether mutations that are linked to rheumatoid arthritis are likely to have effects on receptor function. Since the crystal structure of DR3 is not known, comparative modeling was used, aligning structural elements of the primary sequences of DR3 with TNFs which have been determined by crystallography, substituting the amino acids of the target protein for those in the known structure, introducing necessary deletions or insertions, followed by energy minimization to yield a putative structure. This approach has been validated by studies of other TNF-family receptors. The results show that the DR3 extracellular domain is comprised of four homologous cysteine-rich domains (CRDs), and that a mutation linked to rheumatoid arthritis is in a region critical for structural integrity of ligand-receptor complexes at the end of CRD3. Specifically, the D158G mutation eliminates two hydrogen bonds normally present in a N/D-T-V/D-C consensus motif typically found flanking the last cysteine of each CRD. This may cause aberrations in either T cell function or in response of bone cells to DR3 ligands, which may contribute to pathology in rheumatoid arthritis. Comparison of RA mutants to mutants in other TNFRSF receptors shows that these occur in homologous positions in CRDs, so that this site is proposed to be a 'hot spot' for mutations in TNFRSF family proteins.

0 Bookmarks
 · 
57 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Many variants of the DR3/LARD death receptor mRNA are derived during alternative splicing. Different DR3/LARD mRNAs encode the membrane and soluble forms of the receptor, which perform different functions. The frequency of the spliced mRNA variants of DR3/LARD was assessed by RT-PCR in patients with colorectal cancer and in cancer cell lines. Four forms of the DR3/LARD death receptor mRNA were detected with different frequencies in the studied samples. Two of them encoded the membrane molecules (LARD 1a mRNA and DR3β mRNA) and two other forms expressed the soluble forms of the receptor (LARD 3 mRNA and soluble DR3β mRNA). In the blood of healthy volunteers, 11 variants (spectra) of DR3/LARD mRNA forms were identified, and the full spectrum that included all four variants of DR3/LARD mRNA dominated. In blood and tumor center samples from patients with colon cancer, six spectra of DR3/LARD mRNA were found. The diversity of the DR3/LARD mRNA spectra was decreased in colon cancer patients due to the reduced frequency of soluble DR3β mRNA. In samples of tumor centers, the spectrum with the absence of only mRNA of the soluble DR3β form dominated. In the blood of patients, two spectra prevailed, i.e., the full spectrum and LARD 1a mRNA and LARD 3 mRNA. Only these two spectra of DR3/LARD mRNA were also found in cancer cell lines. Distinctions in the frequency of DR3/LARD mRNA spectra in healthy volunteers and patients with colorectal cancer can define the different susceptibility of immunocompetent and tumor cells to apoptosis signals.
    Molecular Biology 09/2013; 47(5):721-726. DOI:10.1134/S0026893313050208 · 0.74 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Strontium (Sr), chemical element number 38, has a content in normal diets of 0.022-0.046 mmol/day and its physiological levels are between 0.11-0.31 mmol/l. Its behaviour is similar to that of calcium. It is distributed in plasma, extracellular liquid, soft tissues and skeleton. It binds to serum proteins and is eliminated through urine and faeces. If administered alone, 25-30% is absorbed and this absorption is diminished if it is administered with calcium or food. Although absorbed both actively and passively, active absorption is vitamin-D dependent. As a divalent cation, Sr is not metabolized.In studies carried out with animals, it was shown not to have toxic effects on bone cells or on mineralization, if the doses are less than 1% of the diet (low dose ≤ 4 mmol Sr/Kg/day). A high dose of Sr induces skeletal abnormalities (rickets, mineralization defects) especially in animals with a calciumpoor diet.In studies performed, Sr inhibits bone resorption and increases the replication of pre-osteoblastic cells and secondarily the synthesis of collagen matrix.Strontium ranelate (rSr) comprises an organic part (ranelic acid) and two atoms of strontium, is absorbed orally and its absolute bioavailability is 20-25%. Sr binds little to proteins and has a great affinity for bone tissue. rSr has “in vitro” effects on bone cells, increasing DNA synthesis and the synthesis of collagen and non-collagen proteins.rSr inhibits bone resorption as it diminishes the differentiation of pre-osteoclasts and increases the replication of pre-osteoblastic cells, thus increasing bone formation.The Phase II studies with different doses of rSr versus placebo, in order to assess the dose and side effects, it can be summarized by saying that the minimum effective dose of rSr to prevent serious bone loss is 1 g/day and a dose of 2 g/day offers the best combination of efficacy.Two Phase III placebo-controlled studies conducted with 2 g/day of rSr, one into the prevention of vertebral fractures (SOTI) and the other into peripheral fractures (TROPOS), have found vertebral fractures to be reduced by 49% in the first year and by 41% after three years, with BMD increased by +6.8% and +8.1%, already adjusted, versus the baseline values and placebo, respectively.With respect to non-vertebral fractures (TROPOS) in women at high risk of fractures (women ≥ 74 years of age and femoral neck BMD of T ≤ -3), it is associated with a 36% reduction in the risk of hip fractures. The increase, compared with baseline values and placebo respectively, is +2.85% and +4.1% in femoral neck BMD and +3.58% and +4.9% in total hip, all figures also corrected.Bone alkaline phosphatase is increased and C-telopeptide diminished.Adverse events were scant and the most frequent was diarrhoea (6.1%), which disappeared after the first three months.rSr induces to the reduction in vertebral and non-vertebral fractures, is well tolerated and can be a useful therapy for the prevention of osteoporotic fractures in women with osteoporosis.
    Seminarios de la Fundación Española de Reumatología 06/2005; 6(2):43–52. DOI:10.1016/S1577-3566(05)74484-5
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Atsttrin, a progranulin (PGRN)-derived molecule composed of three TNFR-binding domains of PGRN, binds to TNF receptors (TNFR) and is therapeutic against inflammatory arthritis. Here we screened the associations of Atsttrin and other members in TNFR subfamily, which led to the discovery of TNFRSF25 (DR3) as an additional Atsttrin-interacting member in TNFR family. Similar to TNFR1 and TNFR2, DR3 also directly bound to Atsttrin. The first three cysteine-rich domains (CRD) in the extracellular portion of DR3 were required for this interaction. Atsttrin inhibited the interaction between DR3 and its TNF-Like Ligand 1A (TL1A). In addition, Atsttrin inhibited TL1A-stimulated target gene expressions and neutralized TL1A-enhanced osteoclastogenesis in vitro. Furthermore, Atsttrin ameliorated the pathology in dextran sulfate sodium induced colitis. Taken together, these findings not only provide the new insights into Atsttrin's therapeutic action in inflammatory arthritis, but may also present Atsttrin as a novel biological agent for treating various types of diseases associated with TL1A/DR3 pathway.
    PLoS ONE 03/2014; 9(3):e92743. DOI:10.1371/journal.pone.0092743 · 3.53 Impact Factor